Showing results (1691-1700 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|April 8, 2003
Breast cancer management: quality-of-life and cost considerationsDavide Radice, Alberto RedaelliPharmacoeconomics|March 12, 2003
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis CJens Rasenack, Stefan Zeuzem, S Victor Feinman, et al.Pharmacoeconomics|June 28, 2003
Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipientsKaren L Rascati, Michael T Johnsrud, M Lynn Crismon, et al.Pharmacoeconomics|March 19, 2021
Resource Utilization of Patients with Parkinson's Disease in the Late Stages of the Disease in Germany: Data from the CLaSP StudyChristopher Kruse, Sabrina Kretschmer, Anna Lipinski, et al.Pharmacoeconomics|November 17, 2021
The EQ-5D-5L Valuation Study in EgyptSahar Al Shabasy, Maggie Abbassi, Aureliano Finch, et al.Pharmacoeconomics|December 6, 2021
Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over TimeGemma E Shields, Becky Pennington, Ash Bullement, et al.Pharmacoeconomics|February 20, 2019
Correction to: Parental Health Spillover in Cost‑Effectiveness Analysis: Evidence from Self‑Harming Adolescents in EnglandSandy Tubeuf, Eirini-Christina Saloniki, David CottrellPharmacoeconomics|March 11, 2019
Correction to: Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities?Paul Mark Mitchell, Sridhar Venkatapuram, Jeff Richardson, et al.Pharmacoeconomics|March 17, 2019
Dementia Family Caregivers' Willingness to Pay for an In-home Program to Reduce Behavioral Symptoms and Caregiver StressEric Jutkowitz, Danny Scerpella, Laura T Pizzi, et al.Pharmacoeconomics|March 16, 2019
Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular DiseaseYawen Jiang, Weiyi NiPageof 336